Table 1.
Baseline demographics for the mITT population
| Characteristic | ETN 50 mg–ETN 25 mg (n = 21) | ETN 25 mg–ACT 10 mg (n = 19) | ACT 10 mg (n = 18) | Total (N = 58) |
|---|---|---|---|---|
| Mean age, y (SD) | 38.6 (9.5) | 35.5 (8.8) | 42.4 (12.0) | 38.8 (10.3) |
| Mean height, cm (SD) | 169.5 (9.3) | 171.7 (5.5) | 170.9 (6.8) | 170.6 (7.4) |
| Mean weight, kg (SD) | 74.1 (16.0) | 74.0 (11.6) | 74.2 (9.8) | 74.1 (12.7) |
| Gender, n (%) | ||||
| Male | 16 (76.2 %) | 17 (89.5 %) | 15 (83.3 %) | 48 (82.8 %) |
| Cigarette status, n (%) | ||||
| Prior cigarette usage | 5 (23.8 %) | 5 (26.3 %) | 3 (16.7 %) | 13 (22.4 %) |
| Current cigarette usage | 10 (47.6 %) | 11 (57.9 %) | 10 (55.6 %) | 31 (53.5 %) |
| No | 6 (28.6 %) | 3 (15.8 %) | 5 (27.8 %) | 14 (24.1 %) |
| Alcohol status, n (%) | ||||
| Ex-drinker | 2 (9.5 %) | 2 (10.5 %) | 2 (11.1 %) | 6 (10.3 %) |
| Current-drinker | 13 (61.9 %) | 13 (68.4 %) | 11 (61.1 %) | 37 (63.8 %) |
| No | 6 (28.6 %) | 4 (21.1 %) | 5 (27.8 %) | 15 (25.9 %) |
| Prior therapies for psoriasis, n (%) | ||||
| Methotrexate | 2 (9.5 %) | 1 (5.3 %) | 0 | 3 (5.2 %) |
| Cyclosporine | 2 (9.5 %) | 2 (10.5 %) | 1 (5.6 %) | 5 (8.6 %) |
| PUVA | 0 | 3 (15.8 %) | 0 | 3 (5.2 %) |
| Othera | 12 (57.1 %) | 12 (63.2 %) | 10 (55.6 %) | 34 (58.6 %) |
Abbreviations: ACT acitretin, CS clinically significant, ETN etanercept, mITT modified intent-to-treat population, NCS not clinically significant, PUVA psoralen plus ultraviolet A radiation therapy, SD standard deviation
aIncludes systemic antimycobacterials, medication for treating alimentary tract and metabolism conditions, cardiovascular drugs, respiratory drugs, dermatologicals, and systemic hormonal preparations